CLARITIN REDITABS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Claritin Reditabs, and what generic alternatives are available?
Claritin Reditabs is a drug marketed by Bayer Healthcare Llc and is included in two NDAs.
The generic ingredient in CLARITIN REDITABS is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and forty-nine suppliers are listed for this compound. Additional details are available on the loratadine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin Reditabs
A generic version of CLARITIN REDITABS was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.
Summary for CLARITIN REDITABS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 148 |
Clinical Trials: | 3 |
Patent Applications: | 3,870 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CLARITIN REDITABS at DailyMed |
Recent Clinical Trials for CLARITIN REDITABS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Merck Sharp & Dohme Corp. | |
Ranbaxy Laboratories Limited | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for CLARITIN REDITABS
US Patents and Regulatory Information for CLARITIN REDITABS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 021993-001 | Dec 12, 2006 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLARITIN REDITABS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
Bayer Healthcare Llc | CLARITIN REDITABS | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-002 | Nov 27, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CLARITIN REDITABS
See the table below for patents covering CLARITIN REDITABS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Finland | 853675 | ⤷ Try a Trial | |
Denmark | 173765 | ⤷ Try a Trial | |
South Korea | 850000744 | ⤷ Try a Trial | |
Germany | 3573600 | ⤷ Try a Trial | |
Italy | 1158951 | PROCEDIMENTO PER PREPARARE CONFEZIONI CHE CONTENGONO UNO O PIU' ARTICOLO SAGOMATI CHE SUPPORTANO COMPOSTI CHIMICI E CONFEZIONI COSI' PREPARATE | ⤷ Try a Trial |
Japan | H0859657 | PIPERIDIDENEDIHYDRODIBENZO(A,B)CYCLOHEPTENE COMPOUND AND MEDICINE COMPOSITION CONTAINING SAME | ⤷ Try a Trial |
Malaysia | 8700761 | NOVEL ANTIHISTAMINES PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLARITIN REDITABS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0152897 | C00152897/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
1110543 | SPC/GB08/005 | United Kingdom | ⤷ Try a Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
0152897 | 2001C/013 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
0152897 | SPC/GB01/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
1110543 | 08C0004 | France | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |